Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
August 28, 2006
- NEW PRODUCTS
August 28, 2006
- COMMENTARY／Korosho Gets Involved to Eliminate Provisional Delivery
August 28, 2006
- Drug Development Beyond Borders -Today's Global Cooperative Clinical Trials-
August 28, 2006
- Drug Firms Should Support Job Sharing between Regional Med. Institutions: Mr Matsubara
August 28, 2006
- Use of Generic Drugs Increasing at Tokyo Municipal Hospitals
August 28, 2006
- Drug Makers Actively Outsourcing to India: MediBic
August 28, 2006
- Doctors Object to Generics Use Promotion Service
August 28, 2006
- Drug Development Beyond Borders -Today's Global Cooperative Clinical Trials-
August 21, 2006
- JMA Demands Elimination of Losses Related to Consumption Tax
August 21, 2006
- OPINION／The Power of Positive People
August 21, 2006
- SJP to Organize Periodical Seminars on Regulatory Affairs
August 21, 2006
- MEDICAL DEVICE NEWS IN BRIEF
August 21, 2006
- REGULATORY NEWS IN BRIEF
August 21, 2006
- Gov't-Administered Health Insurance to Return to Deficit in FY2006
August 21, 2006
- SELF-MEDICATION NEWS IN BRIEF
August 21, 2006
- Kenporen Member Societies Report Surplus 3 Years in a Row in FY2005
August 21, 2006
- New Antibody Manufacturing Technology Established: Chiome Bioscience
August 21, 2006
- Korosho to Review Its Gastric Cancer Detection Program
August 21, 2006
- SymBio Initiates PI Clinical Trial of Bendamustine
August 21, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…